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Leukotriene A4 hydrolase (LTA4H) is a key enzyme in the inﬂammatory process of mammals. It is an
epoxide hydrolase and an aminopeptidase of the M1 family of the MA clan of Zn-metallopeptidases.
We have solved the crystal structure of LTA4H in complex with N-[3(R)-[(hydroxyamino)carbonyl]-
2-benzyl-1-oxopropyl]-L-alanine, a potent inhibitor of several Zn-metalloenzymes, both endopep-
tidases and aminopeptidases. The inhibitor binds along the sequence signature for M1 aminopepti-
dases, GXMEN. It exhibits bidentate chelation of the catalytic zinc and binds to LTA4H’s
enzymatically essential carboxylate recognition site. The structure gives clues to the binding of this
inhibitor to related enzymes and thereby identiﬁes residues of their S10 sub sites as well as strategies
for design of inhibitors.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc metal-
loenzyme possessing an aminopeptidase as well as an epoxide
hydrolase activity. Whereas the former activity is yet of unknown
physiological relevance the latter catalyzes the formation of the
potent chemotaxin leukotriene B4 (LTB4), a substance which is fun-
damental to the inﬂammatory response of mammals and possibly
all vertebrates. Even though the immediate effect of LTB4 is neutro-
phil recruitment, which is elicited already at nanomolar concentra-
tions [1], LTB4 is also known to modulate the immune response [2],chemical Societies. Published by E
ra-nitroanilide; LTA4, leuko-
E, sodium dodecyl polyacryl-
ce liquid chromatography;
nzyl-1-oxopropyl]-L-alanine
able at the Protein Data Bank
(F. Tholander), jesper.haegg-
gy and Functional Genomics,to participate in the host-defense against infection [3], to regulate
lipid metabolism [4] and to be a key-mediator of the lethal effect of
PAF-induced systemic shock [5,6]. Elevated levels of LTB4 have
been detected in afﬂicted tissues of several inﬂammatory diseases,
e.g., rheumatoid arthritis [7], inﬂammatory bowel disease [8] and
psoriasis [9]. It has recently been demonstrated that LTA4H is
upregulated in atherosclerotic plaques of humans thus suggesting
a role for LTB4 in cardiovascular disease [10]. Furthermore, recent
reports have shown that LTB4 also mediates recruitment of certain
T-cells to the site of inﬂammation, thereby identifying LTB4 as a
link between the innate and adaptive immune response [11–13].
Since LTB4 is undoubtedly of pathological relevance it is partic-
ularly interesting to control its biosynthesis as a means to treat dif-
ferent inﬂammatory disorders. To this end, the development and
analysis of efﬁcient inhibitors targeted against LTA4H is highly
interesting. Here we report the crystal structure of LTA4H in com-
plex with N-[3(R)-[(hydroxyamino)carbonyl]-2-benzyl-1-oxopro-
pyl]-L-alanine (kelatorphan), a di-peptide related substance in
which the a-amino group has been replaced by a bidentate me-
tal-chelating hydroxamic acid moiety.
Kelatorphan was originally designed to inhibit the endopepti-
dase neprilysin (Ki 2 nM) but was subsequently found to be potentlsevier B.V. All rights reserved.
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LTA4H (Ki of 5 nM), even though it does not contain the free amino
group typically required for recognition by aminopeptidases [14–
16]. Here we report the crystal structure of LTA4H in complex with
kelatorphan, which reveals a binding arrangement relying on a
conserved sequence motif (GXMEN of M1 aminopeptidases),
strong zinc chelation and binding to LTA4H’s carboxylate recogni-
tion site. Since binding of kelatorphan relies on conserved struc-
tural elements it is possible to extrapolate our ﬁndings to other
homologous Zn metallo enzymes.
2. Materials and methods
2.1. Materials
Leukotriene A4 (LTA4) methyl ester was purchased from BIO-
MOL Res. Lab, Plymouth Meeting, PA, USA and saponiﬁed in tetra-
hydrofuran with 1 M LiOH (6% v/v) for 48 h at 4 C. Bradford
protein dye-reagent was from Bio-Rad (Bio-Rad Laboratories AB,
Sweden) and other chemicals were from Sigma (Sigma–Aldrich
Sweden AB, Sweden). Kelatorphan was synthesized as described
[17,18].
2.2. Protein expression and puriﬁcation
Expression of (His)6-tagged protein in Escherichia coli and sub-
sequent puriﬁcation with Ni-afﬁnity chromatography followed by
anion exchange chromatography was performed as previously de-
scribed [16,19]. The ﬁnal anion exchange step was only performed
on protein preparations used for crystallization. The protein purity
was assessed by sodium dodecyl polyacrylamide gel electrophore-
sis (SDS–PAGE) using 10–15% gradient gels on a Pharmacia phast
system. Protein concentration was determined according to the
Bradford method using bovine serum albumin as standard. To ver-
ify the functional integrity of the protein, the tri-peptidase activity
was conﬁrmed with a recently described novel methodology utiliz-
ing competing substrates [20].
2.3. Aminopeptidase inhibition assays
Five sets of initial velocity measurements were performed.
Within a set, substrate concentration was varied while concentra-
tion of inhibitor was kept constant. Inhibitor concentration was
varied between sets. The complete experiment was repeated 3
times.
Aliquots (50 ll) of equilibrated solutions containing 1 lg pro-
tein, 500 mM KCl, 250 mM Tris–HCl pH 7.5 and various amounts
of inhibitor were added to the wells of a microtiter plate. Reactions
were initiated by the addition of 200 ll of ala-p-NA of various con-
centrations. The amount of para-nitroaniline (p-NAn) formation
was monitored for 15 min in a MCC/340multiscan spectrophotom-
eter as increase in absorbance at 405 nm. To correct for spontane-
ous hydrolysis of ala-p-NA, absorbance of incubations without
enzyme was subtracted. A molar response factor of 8065 M1
was used for p-NAn.
2.4. Epoxide hydrolase inhibition assay
Three sets of dose-response measurements with constant sub-
strate concentration and varied inhibitor concentration were per-
formed. Aliquots (100 ll) of 50 mM Tris–HCl pH 8.0 containing
2.5 lg of protein and various amounts of inhibitor were incubated
for 20 min on ice. Reactions were initiated by addition of 1 ll LTA4
(ﬁnal concentration 150 lM) and stopped after 15 s with 200 ll of
methanol, containing PGB2 as internal standard. Samples were
subsequently diluted with 1 ml water and acidiﬁed with 10 ll ofacetic acid (10%). Metabolites were isolated by solid phase extrac-
tion on Chromabond C18 columns. Samples were loaded on the
columns and washed with 1 ml 25% methanol followed by extrac-
tion with 250 ll 100% methanol. Extracted samples were diluted
with 250 ll water and subsequently analyzed by high performance
liquid chromatography with a Waters Nova-Pak C18 column and
isocratic elution with methanol/acetonitrile/water/acetic acid
(30:30:40:0.01 by volume) at a ﬂow rate of 1.2 ml/min. Metabo-
lites were detected by their UV absorbance at 270 nm and quanti-
ﬁed using Chromatography Station for Windows version 1.7
computer software. Calculations were based on peak area mea-
surements and the known extinction coefﬁcients for the internal
standard PGB2 (30 000 M1  cm1) as well as LTB4 (50 000 M1 
cm1).
2.5. Determination of kinetic parameters
Data obtained from the aminopeptidase inhibition assay was
analyzed using the Dynaﬁt program [21]. The program numerically
ﬁts various models for inhibition to the data and performs model
discrimination analysis. Ki values from the model obtaining the
highest statistical signiﬁcance are reported and standard errors
are the ones calculated by the software.
For determination of IC50 values, a standard four parameter Hill
equation (with parameters for top and bottom plateaus set to con-
stant values) was ﬁtted to the data and the model-to-data ﬁt ana-
lyzed using the Solverstat software [22].
2.6. Crystallization
Crystals of LTA4H complexed with kelatorphan were obtained
by co-crystallization of enzyme and inhibitor using the liquid–li-
quid diffusion method described previously [19]. Brieﬂy, 5 ll of
precipitation solution (28% (v/v) PEG8000, 50 mM sodium acetate,
0.1 M imidazole buffer, pH 6.8, and 5 mM YbCl3), was injected into
the bottom of a melting point capillary and an equal volume of
LTA4H (5 mg/ml) in 10 mM Tris–HCl, pH 7.5, containing 1 mM
kelatorphan, was layered on top.
2.7. Diffraction data collection
For data collection, crystals were soaked in 14% (w/v) PEG8000,
25 mM sodium acetate, 50 mM imidazole buffer, pH 6.8, 2.5 mM
YbCl3 and 25% (v/v) glycerol. Data was collected at the beamline
I711 of Max-Lab, Lund, Sweden. During data collection the crystal
was kept under a stream of liquid nitrogen. A complete set of data
was collected from one single crystal.
2.8. Data processing and reﬁnement
Diffraction data were processed with Mosﬂm [23] and programs
of the CCP4 program suit [24]. As a starting model for the reﬁne-
ment the crystal structure of [E271Q]LTA4H was used (PDB ID
1H19). Prior to initial reﬁnement all solvent and ligand atoms, ex-
cept the active site Zn ion were removed, and all B-factors set to 15.
The same set of reﬂections (mounting to 3.3% of the data set) as in
the starting model was set aside for the Rfree calculations. Reﬁne-
ment was performed according to the maximum likelihood princi-
ple using refmac5 software [25]. In the initial rounds of reﬁnement
the protein was treated as a rigid body followed by a restrained
reﬁnement including isotropic B-factors. Manual model building
and interpretation of electron density maps was then performed
with the XtalView program [26]. While monitoring the R values,
additional rounds of automatic building of solvent atoms and re-
strained reﬁnement interspersed with manual model building
was then performed until the structures converged. Figures were
Table 1
Data collection and reﬁnement statistics. Values for the highest resolution shell are
given in parenthesis.
KelatorphanLTA4H
Data collection statistics
Resolution range (Å) 15–1.9
k (Å) 1.089
Rmerge
a (%) 8.7 (25)
Completeness (%) 97.5 (96)
No. of unique reﬂections 52 364
Mean I/r 9.8 (2.9)
Multiplicity of observation 3.5 (2.5)
Cell dimensions (Å) a = 77.83; b = 87.14; c = 99.19
Cell dimension () a = b = c = 90
Space group P212121
Reﬁnement
Resolution range (Å) 14.65–1.9
Rfactor
b 17.0
Rfree
c 21.7
Rmsd of bond length (Å) 0.021
Rmsd of bond angle () 1.77
Average B main chain (Å2) 11.4
Average B side chain (Å2) 14.6
Average B waters (Å2) 19.8
Average B inhibitor (Å2) 15
Ramachandrand (%) 7.2, 0.4, 0
No. of water molecules 420
Other non-protein residues Zn2+, Yb3+, acetate, kelatorphan, imidazole
a Rmerge = RjRh|Ihj  Ih|/RjRhIjh - where Ihj is the jth observation of reﬂection h and
Ih is the weighted mean of all measurements of h.
b Rfactor = Rj|Fobs  Fcalc)|/R|Fobs| - where Fobs and Fcalc are the observed and cal-
culated structure factor amplitudes, respectively.
c Rfree is the Rfactor calculated for the test set of reﬂections (3.3%), which are
omitted during the reﬁnement process.
d Fraction of non-glycine residues in additionally allowed, generously allowed
and disallowed regions of the Ramachandran plot.
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3. Results and discussion
3.1. Protein expression and puriﬁcation
From 4.5 l of cell culture approximately 10 mg of recombinant
protein was obtained. After puriﬁcation, LTA4H appeared as a sin-
gle band on an SDS–PAGE gel. Protein concentration was deter-
mined and adjusted to approximately 5.0 mg/ml.
3.2. Enzyme inhibition assays
For the peptidase activity Ki was determined to 9.0 ± 2.5 nM, in
agreement with a previous report [14]. For the epoxide hydrolase
activity IC50 was determined to 170 ± 30 nM (corresponding to a
Ki of 11 nM at the given assay conditions). Thus, both assays gave
similar results for the inhibitory potency of kelatorphan. An at-
tempt to test the inhibitor potency in a whole cell assay was also
made, but the effect of the inhibitor was weak and an accurate
IC50 value could not be determined (IC50 10 lM), in agreement
with a previous report [14]. The high polarity of kelatorphan
(log P ¼ 0:2; logD @ pH7:4 ¼ 3:37) prevents it from entering
the cell interior and explains its weak effect in the whole cell assay.
3.3. Crystallization, X-ray data collection and structure reﬁnement
Plate-like crystals were obtained by the liquid–liquid diffusion
method and appeared within two to three weeks after set up. Data
collection statistics, cell parameters and space groups are given in
Table 1.
3.4. Model building
The ﬁnal reﬁned model is of good quality with well-deﬁned
electron density for all residues except for a few residues in the
N- and C-termini. Electron density for the inhibitor was clearly vis-
ible in the initial Fo–Fc difference map of the starting model and the
inhibitor could be modeled unambiguously with full occupancy
with B-factors in the same range as the surrounding protein atoms
(Fig. S1). For additional reﬁnement statistics and model quality
data see Table 1.
3.5. Crystal structure of kelatorphan in complex with LTA4H
Kelatorphan binds in an extended beta-sheet conformation be-
tween the zinc ion and Arg-563 (Fig. 1). The carboxyl moiety forms
two hydrogen bonds with Arg-563, and the hydroxamate moiety
chelates the zinc ion in a bidentate fashion. Due to chemical simi-
larities, the binding mode of kelatorphan is interesting to compare
with those of tri-peptide substrates (Arg–Ser–Arg and Arg–Ala–
Arg, PDB IDs 3B7S and 3B7T) and phosphinic acid inhibitors
(RB3040 and RB3041, PDB IDs 3B7R and 2R59), described previ-
ously [27]. Thus, the interaction between the carboxy terminus
of kelatorphan and the enzyme is identical with the corresponding
interactions for substrates and transition state analogues. The zinc
chelation is slightly asymmetric with coordinate bond distances of
2.1 and 2.3 Å for the zinc-carbonyl oxygen and the zinc-hydroxyl
oxygen, respectively. This results in a slightly distorted square
based pyramidal total coordination geometry of the zinc ion.
The phenylalanine moiety of kelatorphan occupies the same po-
sition as the corresponding P10 side-chain of the RB3040 and
RB3041 inhibitors. However, in one of these structures
(LTA4HRB3041) the plane of the phenyl ring of the inhibitor is ro-
tated by approximately 90 with respect to the corresponding ringof the other complexes (indicated with a curved arrow in the lower
panels of Fig. 1). The methyl moiety of kelatorphan, which is equiv-
alent to a P20 alanine residue, binds at a position corresponding to
the P20 phenyl group of RB3041 or arginyl side chains of the tri-
peptide substrates. Because the sub-pocket here is large, the
methyl moiety of kelatorphan does not form any clear interactions
with the enzyme.
Interestingly, kelatorphan and the phosphinic acid inhibitors
(RB3040 and RB3041) exhibit similar inhibition potencies towards
LTA4H suggesting that the sum of the stabilizing interactions are
similar in the different complexes. Consistent with this assump-
tion, the structural data show that metal binding (penta-valent
zinc coordination geometry), binding along the conserved GXMEN
motif and carboxylate binding by Arg-563 are very similar in the
structures and thus constitute the main determinants for inhibi-
tion potency. The small differences in binding afﬁnities are ex-
plained by the different side-chains.
In the overall structure, kelatorphan does not induce any signif-
icant structural changes compared to previously analyzed inhibi-
tors. For instance, compared to the LTA4HRB3041 structure, the
root mean square deviation between all backbone atoms is
0.23 Å. In the active site, the only residue that has adopted a signif-
icantly different conformation is Gln-136, which exhibits a 90 dif-
ference in its Cc-Cd dihedral between the two structures. This
torsional twist is induced by the differing P1 residue: while kelat-
orphan lacks such a side chain RB3041 possesses a P1 phenylala-
nine moiety.
3.6. Binding of kelatorphan to other aminopeptidases
In addition to LTA4H and human APN, kelatorphan also inhibits
other aminopeptidases of the M1 family [18,28]. We here present
the ﬁrst example of a structure of this compound bound to its
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Fig. 1. Binding of kelatorphan to LTA4H and comparison to RB3041. Top panel: stereo representation of kelatorphan and selected key residues. For comparison, the structure
is superimposed onto a previously solved structure of LTA4H complexed with the phosphinic acid inhibitor RB3041 [27]. Carbon atoms of the LTA4Hkelatorphan structure
are shown in pink and of the LTA4HRB3041 structure in green, the zinc ion is shown as a metallic sphere. Middle panel: A schematic description highlighting important
interactions in the binding of kelatorphan by LTA4H. Lower panel: schematic representation of the binding of RB3041 to LTA4H. The protein is shown in black and the bound
inhibitors in gray, selected non-bonding interactions are presented with dotted lines (middle and lower panels). The curved arrow indicates a torsional difference between
kelatorphan and RB3041 (middle and lower panels).
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ing mode of this inhibitor to other members of the M1 family of
aminopeptidases. The basic binding mode of the inhibitor is prob-
ably very similar between different enzymes, since both the zinc
site and the GXMEN sequence motif are conserved among mem-
bers of the M1 family and essential for substrate and inhibitor
binding [15,16,27,29–32].In LTA4H the carboxyl moiety of tri-peptide substrates (the pre-
ferred substrate of LTA4H) binds to Arg-563, a functionality which
is absent in several other aminopeptidases adopted to bind longer
peptides. This is reﬂected by the fact that kelatorphan is a signiﬁ-
cantly weaker inhibitor of human APN, which lacks such a residue,
as compared to LTA4H. Thus, even though kelatorphan is likely to
be active against several other M1 aminopeptidases, its potency
Fig. 2. Structurally corrected sequence alignment of APN, the tricorn interacting factor F3 and LTA4H. Subsequences corresponding to 200 residues of the central catalytic
domain of LTA4H that were used in the alignment are shown. Conserved residues are shaded in green, identical residues in yellow and similar residues in cyan. Positions
marked with a black dot indicate residues in APN or TIFF3 that are within interacting distance of the phenylalanine side chain of kelatorphan and thereby deﬁne potential
residues of the S10 sub-pocket, see Section 3.6 for details. Underneath each block of sequences, a diagram indicates the Euclidian distance between corresponding a-carbons
of each structure. Green trace, LTA4H-TIFF3; blue trace LTA4H-APN; red trace, APN-TIFF3. The sequence alignment was adjusted according to the relative positioning of the
superimposed structures. Brackets ({) mark residues that exhibit poor matching between a-carbon positions where the choice of corresponding residues are ambiguous.
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boxyl moiety.
Besides LTA4H, one archean, two prokaryotic, and one eukary-
otic aminopeptidase of the M1 family of metallopeptidases have
been structurally determined; the tri-tricorn interacting factor F3
from (TIFF3) Thermoplasma acidophilum and APN from E. coli and
Colwellia psychrerythraea, and APN from Plasmodium falciparum
[19,33–37]. Superimposing e.g., LTA4H-APN (E. coli), APN-TIFF3,
and LTA4H-TIFF3 gives root mean square deviations of 1.4 Å for
325 equivalent C-a atoms for LTA4H-APN, 1.8 Å for 281 C-a atoms
of APN-TIFF3, and 1.7 Å for 244 C-a atoms of TIFF3-LTA4H. Signif-
icant parts of the structural elements surrounding the active site
align very well in space (Fig. 2); conclusions regarding functional
conservation of such regions are likely to be reliable.
Since the phenylalanine moiety of kelatorphan corresponds to
the P10 residue of peptide substrates, the S10 sub site and surround-
ing residues of these enzymes can be identiﬁed (Fig. 2). To identify
these residues, the torsions of the P10 phenylalanine moiety of
kelatorphan were scanned. Residues of the structures superim-
posed onto LTA4H, which came close to the P10 side chain, was
then ﬂagged as potential S10 residues (Fig. 2). This allowed a gener-
ous deﬁnition of the S10 sub site. The cutoff criteria for an interact-
ing residue was strictly distance based (4 Å), for instance
sterochemical or energetic effects were not taken into account.
Notably, most identiﬁed residues are located in parts of the
structures that align well in three dimensions, as indicated in
Fig. 2. Extrapolation of the functional role of a particular residue
of LTA4H to other aminopeptidases are more reliable for residues
found in such well-aligned regions, e.g. as seen for the identiﬁed
residues of the S10 sub-pocket (Fig. 2). Sequence alignments would
allow simple identiﬁcation of these residues in yet other M1 ami-
nopeptidases. To experimentally verify their potential role in sub-
strate speciﬁcity, future mutational studies may be utilized.
In conclusion, the LTA4Hkelatorphan crystal structure reveals
that the binding of the inhibitor partly relies on conserved struc-tural elements (the catalytic zinc site and the GXMEN motif of
M1 aminopeptidases) as well as elements unique for LTA4H. There-
fore, it becomes possible to extrapolate our ﬁndings regarding
kelatorphan binding and speciﬁcity to other homologous zinc
metalloenzymes, which in turn may aid in development of isozyme
selective inhibitors that can discriminate between LTA4H and
other zinc aminopeptidases.
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